Hauptdiskussion ISIN: US10501L1061 Forum: Aktien User: Schorsch11

👀

🎈

👍

🙋‍♀️

Significant Market Opportunity • 16.2M Major Depressive Disorder (“MDD”) U.S. adult patients with an $8B+ annual addressable market • 2.2M Obsessive Compulsive Disorder (“OCD”) U.S. adult patients with an $800M+ annual addressable market Established Proprietary Platform Technology • FDA clearance for MDD and OCD; CE Mark for additional indications • Demonstrated efficacy, well-tolerated, and potential to address wider variety of brain disorders • Establishment U.S. reimbursement for MDD treatments; Seeking U.S. reimbursement for OCD treatment High Growth Potential • Strong clinical data in smoking cessation reported in late 2019; working with FDA on next steps • Granted breakthrough device designation for the treatment of opioid use disorder; working on clinical trial • Opportunity to expand into new territories such as Japan Robust Flexible Business Model • Fixed-fee, risk share, and outright purchase options provides physicians tremendous flexibility • For full year 2019, generated revenue of $23.1M, up 41% YoY

Basierend auf dem letzten Q-Bericht ist der Cash-burn ca. 700k$ pro Monat und reicht noch ca. 2 Jahre. Second Quarter 2020 Financial Results Total revenues for the second quarter of 2020 totaled $4.8 million, compared with $5.7 million for the second quarter of 2019, a decrease of 15%. Quarterly recurring lease revenues were $3.4 million, representing an increase of 4% over the second quarter of 2019, and comprised 70% of total revenues. Gross margin for the second quarter of 2020 was 79%, an increase when compared to second quarter 2019 gross margin of 76%, which resulted from lower manufacturing overhead costs in the quarter. Operating expenses for the quarter totaled $4.0 million, compared with $7.0 million for the second quarter of 2019. The decrease is in-line with the Company’s efforts to enhance efficiency and to lower operational expenses in light of the financial impact of COVID-19. Operating loss for the quarter was $0.2 million, compared with an operating loss of $2.7 million for the same period in 2019.   As of June 30, 2020, the Company had cash and short-term investments of approximately $17.8 million, compared to $21.9 million at December 31, 2019, reflecting a cash use of $4.1 million for the first half of 2020 resulting from operating losses and timing of inventory deliveries from vendors. 

As of June 30, 2020, BrainsWay’s Deep TMS installed base was 567 total systems, a 24% increase from the same period in 2019. [The company also] achieved key reimbursement progress for Deep TMS in major depressive disorder Its flagship technology is based on Deep Transcranial Magnetic Stimulation (TMS) which is used for brain disorder treatment such as treatment of depression in patients. The group earns revenues from the sale and lease of devices.

66 Patente https://patentscope.wipo.int/search/en/result.jsf?_vid=P11-KE70U8-92525 55 klinische Studien https://clinicaltrials.gov/ct2/results?cond=&term=brainsway&cntry=&state=&city=&dist=